LMFA director granted 157,140 options at $1.26 — Form 4 disclosure
LM Funding America, Inc. (LMFA) reported that director Douglas I. McCree received a non-employee director stock option award on 08/27/2025 under the company’s Non-Employee Director Compensation Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
LM Funding America, Inc. (LMFA) reported that director Douglas I. McCree received a non-employee director stock option award on 08/27/2025 under the company’s Non-Employee Director Compensation Plan. The award grants the right to purchase 157,140 shares of common stock at an exercise price of $1.26 per share, exercisable immediately and expiring on 08/27/2035. The options vest one-half 180 days after the grant and the remaining one-half on the first anniversary of the grant date. The filing is a routine disclosure of director compensation and does not include other financial results or transactions.
Insights
TL;DR Director received standard long-term option award to align interests with shareholders; vesting schedule encourages multi-year retention.
The grant of 157,140 options at $1.26 uses the company’s established Non-Employee Director Compensation Plan, indicating governance-level alignment of pay with long-term equity performance. The two-step vesting (50% at 180 days, 50% at one year) is a retention-focused schedule typical for non-employee directors. This is a standard, non-cash compensation event and appears procedural rather than an extraordinary corporate action.
TL;DR Materiality is limited; this is an equity compensation disclosure with potential dilution but no immediate cash impact.
The option award grants rights to 157,140 common shares at $1.26, exercisable through 2035. If exercised, the issuance would increase share count and dilute existing holders; however, the filing contains no indication of immediate exercise or cash proceeds. There is no accompanying financial performance data or other insider trades to suggest a change in company valuation or near-term liquidity impact.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 157,140 | $0.00 | $0.00 |
Footnotes (1)
- F1. Option awards to purchase shares of common stock were granted under the Non-Employee Director Compensation Plan, as amended on November 18, 2022. Shares subject to the options will vest as to one-half on the 180th day after the grant date and as to one-half on the date that is the first anniversary of the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.